Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Cash & Equivalents data on file, last reported at $54.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 51.67% year-over-year to $54.0 million; the trailing twelve-month figure through Mar 2026 stood at $54.0 million (down 51.67% YoY), and the FY2025 full-year result was $84.9 million, down 17.07% from the prior year.
• Cash & Equivalents fell to $54.0 million in Q1 2026, from $84.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $354.2 million in Q1 2023 to a low of $49.4 million in Q3 2022.
• A 5-year average of $115.6 million and a median of $102.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 429.19% in 2023 and slumped 64.66% in 2024, its largest moves.
• Tracing VNDA's Cash & Equivalents over 5 years: stood at $135.0 million in 2022, then gained by 0.59% to $135.8 million in 2023, then dropped by 24.67% to $102.3 million in 2024, then dropped by 17.07% to $84.9 million in 2025, then sank by 36.32% to $54.0 million in 2026.
• Business Quant data shows VNDA's Cash & Equivalents at $54.0 million in Q1 2026, $84.9 million in Q4 2025, and $70.0 million in Q3 2025.